What Emmecell does

Emmecell is a clinical-stage biotechnology company founded in 2016 and headquartered in Menlo Park, California, that develops cell-based therapies using a proprietary Magnetic Cell Delivery nanoparticle platform. The platform uses magnetic nanoparticles to localize, retain, and integrate therapeutic cells at target tissues, addressing a core delivery bottleneck in regenerative medicine. Emmecell's lead product candidate, EO2002, consists of magnetic human corneal endothelial cells designed as a first-in-class, non-surgical treatment for corneal edema — an indication that is currently managed by technically demanding corneal transplantation or endothelial keratoplasty surgery and represents the most common indication for corneal transplantation.

The company is led by CEO Ramin Valian (appointed January 2026, formerly of Allergan and AbbVie), COO Noelia J. Kunzevitzky, PhD, and co-founders Dr. Jeffrey Goldberg (Chair of Ophthalmology at Stanford University) and Dr. Roger Goldberg (vitreoretinal surgeon, Bascom Palmer-trained), with a board that includes James Mazzo, whose career spans CEO roles at Allergan eye care, Advanced Medical Optics, Abbott ophthalmology, AcuFocus, and Carl Zeiss Meditec. Emmecell also operates CellMP, a wholly-owned subsidiary that provides integrated research, process development, cGMP manufacturing, and testing services to external biotechnology companies and startups, generating service revenue and supporting internal pipeline supply.

Emmecell's business model is pre-commercial for its therapeutic pipeline — EO2002 is advancing toward pivotal clinical development, with future revenue expected from therapeutic product sales post-approval. In the near term, CellMP provides contract manufacturing and development revenue from third-party cell therapy clients. The company is privately held, venture-backed, and completed a strategic financing round in June 2026 with participation from Bausch + Lomb, a leading global eye health company, alongside existing investors, with proceeds directed toward clinical advancement and operational expansion.

Name

Emmecell

Legal name

Emmecell

Website

https://emmecell.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

Emmecell is a clinical-stage biotechnology company developing cell therapies using a proprietary magnetic nanoparticle delivery platform, with lead candidate EO2002 targeting corneal edema as a non-surgical alternative to corneal transplantation, supplemented by CellMP cGMP manufacturing services.

Ownership category

akta.pro rank

Product category

Cell Therapy / Ophthalmic Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Ophthalmic Regeneration (cornea/retina) (HLAAAGAK)

akta.pro secondary industries

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC)

Keywords

• Cell therapy development
• Magnetic cell delivery
• Ophthalmic therapeutics
• CGMP manufacturing services
• Regenerative medicine

Headquarters

HQ city

Menlo Park

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Cell Therapy Products: Pre-commercial stage. The company is developing proprietary magnetic cell delivery technologies for ophthalmic diseases with EO2002 in pivotal development stage for corneal edema treatment. Revenue will be generated through therapeutic product sales upon regulatory approval.
2. Contract Manufacturing Services (CellMP): CellMP subsidiary provides cGMP manufacturing and testing services to biotechnology companies and startups, supporting partners from early development through clinical-stage manufacturing.

Go-to-market motion1 record

Marketing channels4 records

Core offering

Emmecell is developing EO2002, a first-in-class cell therapy that uses proprietary magnetic nanoparticles to deliver human corneal endothelial cells to the eye as a non-surgical alternative to corneal transplantation for the treatment of corneal edema. The company also operates CellMP, a subsidiary that provides integrated research, process development, cGMP manufacturing, and testing services to biotechnology companies developing cell-based therapies.

Product overview

Emmecell is a clinical-stage biotechnology company with a unified portfolio built around its Magnetic Cell Delivery Platform—a proprietary nanoparticle technology that enables precise localization and integration of cell therapies to target tissues. The company's primary product is EO2002, a Magnetic Human Corneal Endothelial Cell therapy for treating corneal edema that represents a first-in-class alternative to traditional corneal transplantation surgery. Complementing the platform is CellMP, a cGMP manufacturing subsidiary that provides contract development and manufacturing services for cell-based therapies, supporting both Emmecell's internal pipeline and external biotechnology partners.

Differentiator

Problem solved

Functional benefit

Products and services

• EO2002 - Magnetic Human Corneal Endothelial Cells A first-in-class cell therapy treatment designed to replace corneal surgery by using proprietary magnetic cell delivery to transplant corneal endothelial cells into the eye for the treatment of corneal edema. Targeted at patients with corneal endothelial diseases including Fuchs' dystrophy.
• CellMP cGMP Manufacturing and Process Development Services Contract research, process development, cGMP manufacturing, and testing services for cell-based therapies, supporting biotechnology companies and startups from early development through clinical-stage manufacturing with focus on quality, scalability, and regulatory compliance.

Quantifiable outcome

• No non-surgical procedures currently approved for advanced corneal edema
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• CellMPcoreOthersCellMP is a wholly-owned subsidiary of Emmecell that provides integrated research, process development, cGMP manufacturing, and testing services to biotechnology companies and startups. It supports partners from early development through clinical-stage manufacturing.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Aurion Biotech: Aurion Biotech is developing cell therapies for corneal endothelial diseases, the most directly comparable competitor to Emmecell's EO2002 in the same indication with a similar mechanism of delivering cultivated corneal endothelial cells to patients.

Emerging players

• Trefoil Therapeutics: Trefoil is developing engineered FGF-1-based therapies for corneal endothelial disease and other corneal disorders, competing in the same patient population as Emmecell with a non-cell biologic alternative approach.
• jCyte: jCyte is a clinical-stage cell therapy company developing allogeneic retinal progenitor cells for retinitis pigmentosa and other retinal degenerative diseases, sharing the cell therapy delivery paradigm in ophthalmology though targeting a different ocular tissue.
• Lineage Cell Therapeutics: Lineage Cell Therapeutics develops allogeneic cell therapies for ophthalmic, neurological, and other indications, making it a relevant comparable in regenerative cell therapy with overlapping ophthalmology interest.
• Sigilon Therapeutics: Sigilon (acquired by Eli Lilly) developed cell therapies using engineered biomaterial spheres to deliver therapeutic cells, sharing Emmecell's interest in solving the cell therapy delivery and retention challenge though for non-ophthalmic indications.
• Kala Bio: Kala Bio is a clinical-stage biopharmaceutical company developing novel therapies for rare and serious eye diseases, sharing the ophthalmic specialty pharmaceutical and biotech profile though using a small-molecule rather than cell therapy approach.
• Neurotech Pharmaceuticals: Neurotech Pharmaceuticals develops encapsulated cell therapy implants for chronic retinal diseases; its Executive Chair James Mazzo also sits on Emmecell's board, and the company shares Emmecell's profile as a private clinical-stage ophthalmic cell therapy developer.
• Cellares: Cellares provides automated cell therapy manufacturing technology and services, representing an emerging alternative or potential partner to Emmecell's CellMP cGMP manufacturing subsidiary in scaling cell therapy production.

Broad incumbents

• BlueRock Therapeutics: BlueRock Therapeutics (a Bayer subsidiary) is a leading engineered cell therapy company with a platform approach similar to Emmecell's, though focused on cardiology, neurology, and immunology rather than ophthalmology.
• Lonza Group: Lonza is a global CDMO providing cell and gene therapy manufacturing services comparable to Emmecell's CellMP subsidiary, representing the established incumbent against which CellMP competes and benchmarks for cell therapy manufacturing scale and quality.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/emmecell

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Emmecell